Cargando…

The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis

The 21-gene recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit in early estrogen receptor-positive (ER +) HER2-negative (HER2-) breast cancer (BCA). We evaluated clinicopathologic characteristics, RS and chemotherapy benefit in invasive ductal carcinoma (IDC),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makower, Della, Qin, Jiyue, Lin, Juan, Xue, Xiaonan, Sparano, Joseph A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758772/ https://www.ncbi.nlm.nih.gov/pubmed/35027533 http://dx.doi.org/10.1038/s41523-021-00368-9

Ejemplares similares

Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
por: Makower, Della, et al.
Publicado: (2021)

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Progress in adjuvant chemotherapy for breast cancer: an overview
por: Anampa, Jesus, et al.
Publicado: (2015)

The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
por: Barbi, Mali, et al.
Publicado: (2021)

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
por: Sparano, Joseph A., et al.
Publicado: (2021)

Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
por: Zeng, Yufei, et al.
Publicado: (2020)

A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
por: Sparano, Joseph A., et al.
Publicado: (2017)

Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy
por: Kim, Gina, et al.
Publicado: (2023)

Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases
por: Chen, Wei-Rong, et al.
Publicado: (2019)

ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
por: Wu, San-Gang, et al.
Publicado: (2019)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study
por: Rohan, Thomas E, et al.
Publicado: (2021)

Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study
por: Liu, Kai-Hua, et al.
Publicado: (2019)

Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer
por: Sparano, Joseph A., et al.
Publicado: (2022)

Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
por: Wu, Jiayi, et al.
Publicado: (2020)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

Estimating the overall survival benefit of adjuvant chemo‐endocrine therapy in women over age 50 with pT1‐2N0 early stage breast cancer and 21‐gene recurrence score ≥26: A National Cancer Database analysis
por: Stabellini, Nickolas, et al.
Publicado: (2023)

The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database
por: Choi, In Sil, et al.
Publicado: (2020)

Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
por: Lee, Moo Hyun, et al.
Publicado: (2015)

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013
por: Parsons, Benjamin M., et al.
Publicado: (2016)

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher
por: Ma, Sung Jun, et al.
Publicado: (2020)

A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma
por: Shimagaki, Tomonari, et al.
Publicado: (2023)

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
por: Jayasekera, Jinani, et al.
Publicado: (2021)

Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age
por: Bernhardt, Sarah M., et al.
Publicado: (2020)

Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2021)

Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer
por: Alkushi, Abdulmohsen, et al.
Publicado: (2020)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
por: Solin, Lawrence J., et al.
Publicado: (2013)

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
por: Roy, Arya Mariam, et al.
Publicado: (2023)

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery
por: Wu, San-Gang, et al.
Publicado: (2019)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?
por: Bilani, Nadeem, et al.
Publicado: (2022)

Molecular characterization of breast cancer needle core biopsy specimens by the 21‐gene Breast Recurrence Score test
por: Jakubowski, Debbie M., et al.
Publicado: (2020)

Patterns of Care and Utilization of Radiation for Women With Good-Risk Ductal Carcinoma In Situ: A National Cancer Database Analysis
por: Silver, Benjamin, et al.
Publicado: (2022)

Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis †
por: Ziogas, Ioannis A., et al.
Publicado: (2023)

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer
por: Alvarado, Michael D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pgqpj6o50gci1udrlhcekd5bhm